Search
Psyence Biomedical Ltd
PBMAdd to Watchlist
4.910USD
-0.130-2.58%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
11.27MMarket Cap
LossP/E TTM
More Details of Psyence Biomedical Ltd Company
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
Psyence Biomedical Ltd Info
Ticker SymbolPBM
Company namePsyence Biomedical Ltd
IPO dateDec 10, 2021
CEOMaresky (Neil)
Number of employees12
Security typeOrdinary Share
Fiscal year-endDec 10
Address121 Richmond Street West Penthouse
CityTORONTO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeM5H 2K1
Phone17744604171
Website
Ticker SymbolPBM
IPO dateDec 10, 2021
CEOMaresky (Neil)
Company Executives of Psyence Biomedical Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Marc Balkin
Mr. Marc Balkin
Independent Director
Independent Director
--
--
Dr. Jody Aufrichtig
Dr. Jody Aufrichtig
Chairman of the Board, Strategic Business Development Officer
Chairman of the Board, Strategic Business Development Officer
--
--
Dr. Neil Maresky
Dr. Neil Maresky
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Warwick Corden-Lloyd
Mr. Warwick Corden-Lloyd
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Christopher (Chris) Bull
Mr. Christopher (Chris) Bull
Independent Director
Independent Director
--
--
Dr. Seth Feuerstein
Dr. Seth Feuerstein
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Marc Balkin
Mr. Marc Balkin
Independent Director
Independent Director
--
--
Dr. Jody Aufrichtig
Dr. Jody Aufrichtig
Chairman of the Board, Strategic Business Development Officer
Chairman of the Board, Strategic Business Development Officer
--
--
Dr. Neil Maresky
Dr. Neil Maresky
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Warwick Corden-Lloyd
Mr. Warwick Corden-Lloyd
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Christopher (Chris) Bull
Mr. Christopher (Chris) Bull
Independent Director
Independent Director
--
--
Dr. Seth Feuerstein
Dr. Seth Feuerstein
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Apr 2
Updated: Thu, Apr 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Parallel Advisors, LLC
6.59%
Weiner (Jeffrey David)
2.26%
KAOS Capital Ltd
2.19%
Virtu Americas LLC
0.26%
White Lion Capital LLC
0.09%
Other
88.62%
Shareholders
Shareholders
Proportion
Parallel Advisors, LLC
6.59%
Weiner (Jeffrey David)
2.26%
KAOS Capital Ltd
2.19%
Virtu Americas LLC
0.26%
White Lion Capital LLC
0.09%
Other
88.62%
Shareholder Types
Shareholders
Proportion
Investment Advisor
6.59%
Individual Investor
2.26%
Corporation
2.19%
Research Firm
0.28%
Venture Capital
0.09%
Other
88.60%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
24
159.81K
6.96%
+112.68K
2025Q4
32
30.31K
5.33%
-34.02K
2025Q3
38
319.64K
17.07%
+174.04K
2025Q2
45
357.80K
50.17%
+181.11K
2025Q1
45
167.96K
26.60%
+69.68K
2024Q4
82
948.20K
24.27%
+587.08K
2024Q3
88
169.92K
15.90%
-186.51K
2024Q2
92
159.62K
36.84%
-203.47K
2024Q1
96
157.41K
35.61%
-211.56K
2023Q4
88
18.95K
16.18%
-253.66K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Parallel Advisors, LLC
24.20K
1.05%
--
--
Dec 31, 2025
Weiner (Jeffrey David)
51.85K
2.26%
+51.85K
--
Feb 13, 2026
KAOS Capital Ltd
50.22K
2.19%
--
--
Jan 08, 2026
Virtu Americas LLC
5.93K
0.26%
+4.28K
+258.78%
Dec 31, 2025
White Lion Capital LLC
2.01K
0.09%
+2.01K
--
Dec 04, 2024
BofA Global Research (US)
535.00
0.02%
+1.00
+0.19%
Dec 31, 2025
Stonehage Fleming Financial Services Holdings, Ltd.
90.00
0%
--
--
Dec 31, 2025
AdvisorShares Investments, LLC
--
0%
-860.00
-100.00%
Dec 31, 2025
UBS Financial Services, Inc.
161.00
0.01%
+161.00
--
Dec 31, 2025
Citadel Advisors LLC
--
0%
-1.51K
-100.00%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
0%
AdvisorShares Psychedelics ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jan 14, 2026
Merger
6.25→1
May 01, 2025
Merger
7.97→1
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
Date
Ex-dividend Date
Type
Ratio
Jan 14, 2026
Merger
6.25→1
May 01, 2025
Merger
7.97→1
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
Nov 12, 2024
Merger
75→1
